Interim Financial Report of BB Biotech AG for the First Quarter of 2026

BB Biotech AG, a Swiss holding company headquartered in Kusnacht and listed on both the SIX Swiss Exchange and the German stock exchange, released its interim report for the period ended 31 March 2026 on 24 April 2026. The disclosure was made in compliance with Article 17 of Regulation (EU) No 596/2014 and was transmitted via EQS News, a service of the EQS Group.

Consolidated Loss for Q1 2026

According to the consolidated accounts, BB Biotech reported a loss after tax of CHF 21 million for the first three months of 2026. This figure represents a substantial improvement over the loss of CHF 241 million recorded in the same quarter of the preceding year (Q1 2025). The sharp reduction in the loss highlights a notable turnaround in the company’s financial performance during the early part of the year.

Nature of the Results

As an investment company, BB Biotech’s financial results are heavily influenced by the share‑price development of the portfolio companies in which it holds equity. The reported loss thus reflects the broader performance of the biotech firms within the U.S. and Western European markets, where BB Biotech primarily invests.

Availability of the Report

The full interim report, including detailed financial statements and management commentary, is available on the company’s website at https://www.bbbiotech.com . For further inquiries, stakeholders may contact:

  • Bellevue Asset Management AG Theaterstrasse 12, 8001 Zürich, Switzerland Tel.: +41 44 267 67 00

  • BB Biotech Team – Dr. Christian Koch, Head of Investor Relations – ir@bbbiotech.com

  • Media Relations – Tanja Chicherio – tch@bellevue.ch

  • Investor Relations – Rachael Burri – rbu@bellevue.ch

Context within the Company’s Strategy

BB Biotech, operating in the health‑care sector and focusing on biotechnology, has historically pursued an active repositioning strategy. The company’s recent communications suggest that the improvement in its Q1 loss is part of a broader effort to reduce write‑downs (“Abschlag”) and to reposition its portfolio actively, thereby enhancing shareholder value.

The interim report therefore not only provides a snapshot of the company’s current financial standing but also offers insight into its ongoing strategic adjustments within a dynamic biotech investment landscape.